IGF-1 LR3 research peptide – IGF-1 LR3 (Long R3 IGF-1) is a long-acting analogue of Insul

IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a long-acting analogue of Insulin-like Growth Factor 1 that resists IGFBP binding to drive muscle protein synthesis.

MuscleRecovery
In Stock

Total Price

฿2300

CardCryptoEncrypted checkout

For research & laboratory use only. Not for human consumption.

Half-Life

~20-30 hours

Administration Route

Subcutaneous injection

Potent Anabolic Signal

Long R3 analogue with 3x longer half-life than native IGF-1

Hyperplasia Stimulus

Promotes satellite cell division for new muscle fibre formation

Fat Oxidation

Increases glucose uptake in muscle; shifts fuel to fat

Effect Timeline

Start — Week 1

Muscle fullness increases; satellite cell activation begins

Week 2

Strength gains; muscle repair between sessions accelerated

Week 4

Hyperplasia potential; new fibre formation possible with training

Week 8

Maximum anabolic window; continued training amplifies results

Mechanism of Action

IGF-1 LR3 is a synthetic analogue of Insulin-like Growth Factor 1 carrying a 13-residue N-terminal extension and a Glu3-to-Arg substitution. Together these changes sharply lower its affinity for the insulin-like growth factor binding proteins (IGFBPs), so a much larger free fraction stays active in circulation and the half-life stretches from the roughly 12 minutes of native IGF-1 to about 20 to 30 hours. The peptide binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, and triggers two core cascades: PI3K/Akt/mTOR, which drives ribosomal biogenesis and protein synthesis, and MAPK/ERK, which drives proliferative gene expression. The combined signal pushes muscle satellite cells to proliferate, differentiate and fuse into existing fibres, raising the anabolic capacity of the tissue.

Scientific Research

Why Researchers Choose IGF-1 LR3

IGF-1 LR3, the Long R3 analogue of Insulin-like Growth Factor 1, is studied wherever a long-acting, high-availability IGF-1 signal is needed to probe anabolic and regenerative biology. Because its 20 to 30 hour half-life keeps the IGF-1 receptor engaged far longer than native IGF-1, it is a common tool in:

  • Muscle protein synthesis and hypertrophy signalling studies
  • Satellite cell proliferation, differentiation and myonuclear-accretion research
  • PI3K/Akt/mTOR pathway activation and ribosomal-biogenesis investigations
  • Tissue repair, regeneration and anti-apoptotic survival models
  • Glucose-uptake and nutrient-partitioning experiments in skeletal muscle

IGF-1R Signalling Cascade

IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) with affinity comparable to native IGF-1. IGF-1R is a receptor tyrosine kinase, and once activated it propagates several downstream cascades.

PI3K/Akt/mTOR pathway:

  • PI3K converts PIP2 to PIP3 at the membrane
  • PIP3 recruits Akt (PKB) for activating phosphorylation
  • Active Akt phosphorylates and activates mTORC1
  • mTORC1 engages S6K1 and 4E-BP1, driving ribosomal biogenesis and cap-dependent protein translation

MAPK/ERK pathway:

  • The Ras, Raf, MEK, ERK relay drives proliferative gene expression
  • Promotes cell-cycle entry in satellite cells and other progenitors

Anti-apoptotic signalling:

  • Akt phosphorylates and inactivates pro-apoptotic proteins such as Bad and caspase-9
  • Supports cell survival during high-stress tissue remodelling

Satellite Cell Activation

The most consequential long-term growth mechanism runs through muscle satellite cells, the quiescent stem cells that sit beneath the basal lamina of skeletal muscle fibres. In response to IGF-1R stimulation these cells:

  • Exit quiescence and proliferate
  • Differentiate into myoblasts
  • Fuse with existing fibres and donate new nuclei
  • Allow each fibre to support a larger volume of contractile protein per added nucleus

This satellite cell response is what lets IGF-1 LR3 be associated with lasting increases in muscle fibre nuclear content, rather than only transient anabolic spikes.

IGF-1 LR3 vs GHRH/GHRP Protocols

FeatureIGF-1 LR3GHRH + GHRP (e.g. CJC + Ipamorelin)
MechanismDirect IGF-1R agonismStimulate GH release, then hepatic IGF-1 production
Half-life20 to 30 hours30 minutes to 2 hours
Satellite cellsDirect activationIndirect, via GH-stimulated IGF-1
Glucose regulationSignificant effectMinor

Reconstitution and Storage

Reconstitution: the peptide is degradation-sensitive, so use 0.6% acetic acid solution rather than plain bacteriostatic water for optimal stability; swirl gently until dissolved, do not shake. After reconstitution: keep the solution refrigerated at 2-8°C and use within roughly three weeks.

For research purposes only. Not for human consumption.

Dosing at a Glance

Route

Subcutaneous injection

Frequency

Once daily

Typical research dose

20–50 mcg

Calculate dosage

Opens the calculator with this peptide preselected. Research reference only.

Product FAQs

Stacks Well With

Related Products

Cart

Your cart is empty